News articles about Windtree Therapeutics (NASDAQ:WINT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Windtree Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3146519666035 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, Stifel Nicolaus lowered Windtree Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 30th.

Shares of Windtree Therapeutics (WINT) traded down 13.04% during trading on Wednesday, reaching $0.20. The company’s stock had a trading volume of 47,562 shares. The company has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.96. Windtree Therapeutics has a one year low of $0.19 and a one year high of $4.42. The stock’s market cap is $2.06 million.

Windtree Therapeutics (NASDAQ:WINT) last posted its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million during the quarter. On average, equities research analysts forecast that Windtree Therapeutics will post ($2.88) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with's FREE daily email newsletter.